CD274 and neoplasm: By blocking PD-1 interaction with its ligands PD-L1 and PD-L2, dostarlimab restores T-cell-mediated immune responses against tumor cells, effectively enhancing anti-tumor immunity.107 It gained FDA approval in 2021 for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, a subset characterized by high mutational burden and responsiveness to immune checkpoint inhibition.